Given that STING deficiency alongside oncolytic virus treatment is associated with improved prognosis, further in vivo experiments and clinical trials will allow us to develop prognostic and predictive biomarkers for oncolytic immunotherapy for cancer patients. The gene discussed is STING1; the disease is cancer.